Advances in the study of LNPs for mRNA delivery and clinical applications

Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Virus genes Jg. 60; H. 6; S. 577 - 591
Hauptverfasser: Wang, Bili, Shen, Biao, Xiang, Wenqing, Shen, Hongqiang
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New York Springer US 01.12.2024
Springer Nature B.V
Schlagworte:
2019-nCoV Vaccine mRNA-1273
Biocompatibility
Biodegradability
Biomedical and Life Sciences
Biomedicine
Cardiovascular diseases
Cell size
Cholesterol
COVID-19 - prevention & control
COVID-19 infection
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
DNA
DNA biosynthesis
DNA vaccines
Drug delivery
Drug development
genes
Humans
Infectious diseases
Lipid bilayers
Lipids - chemistry
Liposomes
liver
Liver cancer
Liver diseases
Medical Microbiology
mRNA
mRNA Vaccines
Nanoparticles
Nanoparticles - chemistry
pH effects
Phospholipids
Plant Sciences
Polyethylene glycol
Protein biosynthesis
protein synthesis
Review Paper
Ribosomes
RNA
RNA, Messenger - genetics
SARS-CoV-2 - genetics
therapeutics
Transcription
Vaccine development
Vaccine efficacy
vaccines
Vascular diseases
Virology
viruses
mRNA vaccines
mRNA delivery
LNPs
Clinical applications
ISSN:0920-8569, 1572-994X, 1572-994X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.
AbstractList Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.
Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis. The COVID-19 pandemic brought worldwide attention to mRNA vaccines. The emergency use authorization of two COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, were major achievements in the history of vaccine development. Lipid nanoparticles (LNPs), one of the most superior non-viral delivery vectors available, have made many exciting advances in clinical translation as part of the COVID-19 vaccine and therefore has the potential to accelerate the clinical translation of many gene drugs. In addition, due to these small size, biocompatibility and excellent biodegradability, LNPs can efficiently deliver nucleic acids into cells, which is particularly important for current mRNA therapeutic regimens. LNPs are composed cationic or pH-dependent ionizable lipid bilayer, polyethylene glycol (PEG), phospholipids, and cholesterol, represents an advanced system for the delivery of mRNA vaccines. Furthermore, optimization of these four components constituting the LNPs have demonstrated enhanced vaccine efficacy and diminished adverse effects. The incorporation of biodegradable lipids enhance the biocompatibility of LNPs, thereby improving its potential as an efficacious therapeutic approach for a wide range of challenging and intricate diseases, encompassing infectious diseases, liver disorders, cancer, cardiovascular diseases, cerebrovascular conditions, among others. Consequently, this review aims to furnish the scientific community with the most up-to-date information regarding mRNA vaccines and LNP delivery systems.
Author Xiang, Wenqing
Shen, Hongqiang
Wang, Bili
Shen, Biao
Author_xml – sequence: 1
  givenname: Bili
  surname: Wang
  fullname: Wang, Bili
  organization: National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine
– sequence: 2
  givenname: Biao
  surname: Shen
  fullname: Shen, Biao
  organization: Hangzhou Cybernax Biotechnology Co. Ltd
– sequence: 3
  givenname: Wenqing
  surname: Xiang
  fullname: Xiang, Wenqing
  organization: National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine
– sequence: 4
  givenname: Hongqiang
  surname: Shen
  fullname: Shen, Hongqiang
  email: shenhq@zju.edu.cn
  organization: National Clinical Research Center for Child Health, National Children’s Regional Medical Center, The Children’s Hospital, Zhejiang University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39172354$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1PHDEMhiNEBQvtH-ihitRLL9PamSSTOa4QLUgrihCH3qJsPtqg2cw2mUHaf9_AQitxoAfLlvy8Tuz3hBymMXlC3iN8RoDuS0FkkjXAeA0E1sgDskDRsabv-Y9DsoCeQaOE7I_JSSl3AKAU40fkuO2xY63gC3K5dPcmWV9oTHT65WmZZrejY6Crq-tCw5jp5uZqSZ0f4r3PO2qSo3aIKVozULPdDrWY4pjKW_ImmKH4d0_5lNx-Pb89u2hW379dni1XjeWgpkZ6xOCcFFyoYARjwJWzgrUSBXa1sUYeulry2gm9Cq1X4CxI5Y1Zh_aUfNqP3ebx9-zLpDexWD8MJvlxLrpFwVGquuD_UeiFVIjqAf34Ar0b55zqHnUgU6oHlFCpD0_UvN54p7c5bkze6edzVoDtAZvHUrIPfxEE_eCZ3numq2f60TMtq0i9ENk4Pd50yiYOr0vbvbTUd9JPn_99-xXVH1u_p3I
CitedBy_id crossref_primary_10_1016_j_jconrel_2024_12_002
crossref_primary_10_1016_j_omtn_2025_102686
crossref_primary_10_3390_jcm14155515
crossref_primary_10_3390_pharmaceutics17040454
crossref_primary_10_1002_adtp_202500402
crossref_primary_10_1063_5_0281437
crossref_primary_10_1021_acsami_5c06464
crossref_primary_10_1186_s12951_024_02972_w
Cites_doi 10.3390/pharmaceutics12111042
10.1021/bi952000v
10.1016/j.jconrel.2012.12.029
10.1002/adhm.202000938
10.1126/science.abm0594
10.1021/acs.nanolett.6b03329
10.1016/0005-2736(93)90270-A
10.1021/bi950414i
10.1016/j.imlet.2018.01.011
10.1038/s41541-023-00691-1
10.3390/pharmaceutics5030498
10.1038/s41541-020-0163-z
10.1016/j.jconrel.2018.10.008
10.1002/eji.200737998
10.1186/s12943-021-01335-5
10.1038/s41434-019-0095-2
10.1016/j.immuni.2021.11.001
10.1016/j.nano.2012.05.019
10.1021/acs.molpharmaceut.0c00451
10.1056/NEJMoa2105000
10.3390/pharmaceutics14122682
10.1016/j.omtn.2019.01.013
10.1126/science.281.5373.78
10.1021/acsnano.8b03640
10.1111/imr.12621
10.1016/j.addr.2020.12.014
10.1056/NEJMoa2022483
10.1016/j.ejpb.2016.10.016
10.1038/mt.2010.85
10.1038/nature23003
10.1002/anie.202008082
10.1038/s41578-021-00358-0
10.1039/C8TX00005K
10.1016/j.ijpharm.2020.119792
10.1039/C9NR09347H
10.1016/j.vaccine.2020.11.054
10.1016/j.ymthe.2021.03.002
10.1371/journal.pone.0046789
10.1016/j.addr.2012.05.009
10.1089/nat.2018.0721
10.2217/fon-2017-0531
10.3390/ijms21186582
10.3390/vaccines9010065
10.1016/j.chemphyslip.2020.105032
10.1021/acs.accounts.1c00544
10.1016/j.vetmic.2008.10.030
10.1016/j.ymthe.2023.07.022
10.1016/j.cub.2015.05.032
10.1126/science.1690918
10.1016/j.biomaterials.2019.119291
10.1016/j.ijpharm.2021.120586
10.1126/scitranslmed.abn3464
10.1353/bhm.0.0160
10.1016/j.nantod.2019.100766
10.1038/s41551-021-00786-x
10.1016/j.ymthe.2019.01.020
10.1038/s41586-020-2814-7
10.1007/s12274-018-2146-1
10.1016/j.jconrel.2005.06.014
10.1002/anie.201203263
10.1038/mtna.2013.66
10.1016/j.addr.2020.06.002
10.1126/scitranslmed.aao5931
10.1056/NEJMoa2027906
10.1002/smll.202306892
10.1016/j.xphs.2020.12.006
10.1038/nrc.2016.154
10.1038/natrevmats.2017.56
10.1016/j.bcp.2016.05.001
10.1021/acs.chemrev.1c00244
10.1073/pnas.2005191118
10.1021/acsnano.0c10064
10.3389/fimmu.2019.00594
10.1021/mp800049w
10.1038/s41467-021-20903-3
10.1016/j.jconrel.2016.05.059
10.1016/j.isci.2021.103479
10.1016/j.immuni.2020.11.009
10.1126/science.1225829
10.1080/14760584.2017.1355245
10.1016/j.tips.2021.03.002
10.1038/s41541-020-0159-8
10.1016/j.cellimm.2020.104143
10.1016/j.it.2017.05.005
10.1371/journal.pone.0241006
10.1016/j.immuni.2020.07.019
10.1038/mtna.2014.61
10.1177/08971900211009650
10.1039/C9BM01564G
10.1016/j.ijpharm.2019.04.006
10.1056/NEJMoa2028436
10.1016/j.ymthe.2005.09.014
10.1021/acs.nanolett.5b02497
10.1016/j.celrep.2018.11.082
10.1056/NEJMoa2035389
10.1039/C9NR05475H
10.1038/mt.2012.250
10.1016/j.cell.2021.02.030
10.1038/s41467-020-16248-y
10.1016/j.ymthe.2019.02.012
10.1002/adfm.201910575
10.1038/s41467-020-14527-2
10.3390/pharmaceutics13020206
10.1056/NEJMoa2034577
10.1126/science.aan4672
10.1101/cshperspect.a016295
10.1007/s00430-002-0122-5
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TM
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
7S9
L.6
DOI 10.1007/s11262-024-02102-6
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (ProQuest)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database ProQuest
Biological Science Database (ProQuest)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
ProQuest Central Student
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1572-994X
EndPage 591
ExternalDocumentID 39172354
10_1007_s11262_024_02102_6
Genre Journal Article
Review
GrantInformation_xml – fundername: National Key Research and Development Program of China
  grantid: No. 2023YFB3210300
GroupedDBID ---
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
123
1N0
1SB
2.D
203
28-
29Q
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67N
67Z
6NX
78A
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHBH
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSNA
ACZOJ
ADBBV
ADHHG
ADHIR
ADHKG
ADIMF
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDZB
AFEXP
AFGCZ
AFKRA
AFLOW
AFOHR
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHMBA
AHPBZ
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
ATHPR
AVWKF
AXYYD
AYFIA
AZFZN
B-.
BA0
BBNVY
BBWZM
BDATZ
BENPR
BGNMA
BHPHI
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
EPAXT
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GQ8
GXS
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAK
LK8
LLZTM
M1P
M4Y
M7P
MA-
N2Q
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
PF0
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
U2A
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK6
WK8
Y6R
YLTOR
Z45
ZMTXR
ZOVNA
~A9
~EX
~KM
AAYXX
ABFSG
ABRTQ
ACSTC
AEZWR
AFFHD
AFHIU
AHWEU
AIXLP
CITATION
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TM
7U9
7XB
88A
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
7S9
L.6
ID FETCH-LOGICAL-c408t-6e11fdd65458fa522048dc52361517dd6b14f75174204f98f3e80dc068eaabf3
IEDL.DBID RSV
ISICitedReferencesCount 10
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001296493900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0920-8569
1572-994X
IngestDate Sun Nov 09 11:28:53 EST 2025
Thu Sep 04 16:15:18 EDT 2025
Tue Dec 02 09:52:27 EST 2025
Thu Apr 03 07:02:15 EDT 2025
Sat Nov 29 03:30:06 EST 2025
Tue Nov 18 20:42:48 EST 2025
Thu May 22 04:31:30 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords mRNA vaccines
mRNA delivery
LNPs
Clinical applications
Language English
License 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c408t-6e11fdd65458fa522048dc52361517dd6b14f75174204f98f3e80dc068eaabf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 39172354
PQID 3128890160
PQPubID 30539
PageCount 15
ParticipantIDs proquest_miscellaneous_3154168917
proquest_miscellaneous_3095681187
proquest_journals_3128890160
pubmed_primary_39172354
crossref_primary_10_1007_s11262_024_02102_6
crossref_citationtrail_10_1007_s11262_024_02102_6
springer_journals_10_1007_s11262_024_02102_6
PublicationCentury 2000
PublicationDate 20241200
2024-12-00
2024-Dec
20241201
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: 20241200
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: United States
– name: Boston
PublicationTitle Virus genes
PublicationTitleAbbrev Virus Genes
PublicationTitleAlternate Virus Genes
PublicationYear 2024
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Crommelin, Anchordoquy, Volkin, Jiskoot, Mastrobattista (CR23) 2021; 110
Blakney, McKay, Yus, Aldon, Shattock (CR72) 2019; 26
Saxena, Sonwane, Dahiya, Patel, Saini, Rai (CR91) 2009; 136
Patel, Ibrahim, Cheng (CR36) 2021; 42
Ura, Yamashita, Mizuki, Okuda, Shimada (CR87) 2021; 39
Holland, Hui, Cullis, Madden (CR43) 1996; 35
Wolff, Malone, Williams, Chong, Acsadi, Jani (CR10) 1990; 247
Tse, McKinney, Walker, Nguyen, Iacovelli, Small (CR78) 2021; 29
Rusnock (CR82) 2009; 83
Cobb (CR9) 2015; 25
Patel, Ashwanikumar, Robinson, Xia, Mihai, Griffith (CR57) 2020; 11
Song, Zhang, Wu (CR104) 2018; 196
Alameh, Tombácz, Bettini, Lederer, Sittplangkoon, Wilmore (CR74) 2021; 54
Suzuki, Suzuki, Hihara, Kubara, Kondo, Hyodo (CR42) 2020; 588
Tam, Chen, Cullis (CR39) 2013; 5
Karch, Burkhard (CR1) 2016; 120
Kowalski, Rudra, Miao, Anderson (CR73) 2019; 27
Teo (CR2) 2022; 35
Zhang, Maruggi, Shan, Li (CR18) 2019
Jinek, Chylinski, Fonfara, Hauer, Doudna, Charpentier (CR6) 2012; 337
Zhao, Hou, Vick, Dong (CR14) 2019; 217
Lamoot, Jangra, Laghlali, Warang, Singh, Chang (CR79) 2024; 20
Koltover, Salditt, Rädler, Safinya (CR60) 1998; 281
Oberli, Reichmuth, Dorkin, Mitchell, Fenton, Jaklenec (CR55) 2017; 17
Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (CR85) 2020; 383
Ponti, Campolungo, Melchiori, Bono, Candiani (CR27) 2021; 235
Yang, Elankumaran, Marr (CR88) 2012; 7
Pine, Arora, Hart, Bettini, Gaudette, Muramatsu (CR90) 2023; 31
Samaridou, Heyes, Lutwyche (CR29) 2020; 154–155
Aldosari, Alfagih, Almurshedi (CR13) 2021; 13
Rurik, Tombácz, Yadegari, Méndez Fernández, Shewale, Li (CR93) 2022; 375
Kauffman, Dorkin, Yang, Heartlein, DeRosa, Mir (CR61) 2015; 15
Zhang, Leal, Soto, Smyth, Ghosh (CR49) 2020; 12
Yarchoan, Johnson, Lutz, Laheru, Jaffee (CR109) 2017; 17
Snell, McGaha, Brooks (CR108) 2017; 38
Eygeris, Gupta, Kim, Sahay (CR31) 2022; 55
Zhang, Billingsley, Mitchell (CR100) 2018; 292
Ryals, Patel, Acosta, McKinney, Pennesi, Sahay (CR53) 2020; 15
Dunbar, High, Joung, Kohn, Ozawa, Sadelain (CR5) 2018
Lederer, Castaño, Gómez Atria, Oguin, Wang, Manzoni (CR69) 2020; 53
Dinarello (CR65) 2018; 281
Tanyi, Bobisse, Ophir, Tuyaerts, Roberti, Genolet (CR107) 2018
Iavarone, O'Hagan, Yu, Delahaye, Ulmer (CR4) 2017; 16
Tanaka, Takahashi, Konishi, Takata, Akita (CR30) 2020; 30
Lokugamage, Vanover, Beyersdorf, Hatit, Rotolo, Echeverri (CR47) 2021; 5
Chen, Tam, Lin, Sung, Tam, Cullis (CR54) 2016; 235
Grunwitz, Kranz (CR95) 2017; 405
Zhang, You, Wang, Cui, Wang, Xu (CR105) 2021
Lei, Zhang, Men, Gao, Yang, Wu (CR97) 2020; 17
Jackson, Anderson, Rouphael, Roberts, Makhene, Coler (CR62) 2020; 383
Jackson, Kester, Casimiro, Gurunathan, DeRosa (CR8) 2020; 5
Hacisuleyman, Hale, Saito, Blachere, Bergh, Conlon (CR22) 2021; 384
Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman (CR64) 2020; 383
Zhao, Chen, Qiu, Li, Glass, Xu (CR32) 2020; 59
Rizvi, Everton, Smith, Liu, Osota, Beattie (CR94) 2021; 12
Li, Huang (CR50) 2008; 5
Miao, Lin, Huang, Li, Delcassian, Ge (CR52) 2020; 11
Ramos da Silva, Bitencourt Rodrigues, Formoso Pelegrin, Silva Sales, Muramatsu, de Oliveira (CR102) 2023; 15
Tanaka, Narazaki, Kishimoto (CR66) 2014; 6
Lin, Tam, Hafez, Sandhu, Chen, Ciufolini (CR75) 2013; 9
Yang, Arya, Lung, Lin, Huang, Li (CR96) 2019; 11
Sahin, Derhovanessian, Miller, Kloke, Simon, Löwer (CR110) 2017; 547
Gebre, Brito, Tostanoski, Edwards, Carfi, Barouch (CR16) 2021; 184
Laczkó, Hogan, Toulmin, Hicks, Lederer, Gaudette (CR68) 2020; 53
Cui, Wang, Gong, Lin, Zhao, Zhi (CR76) 2018; 7
Heyes, Palmer, Bremner, MacLachlan (CR34) 2005; 107
Baden, El Sahly, Essink, Kotloff, Frey, Novak (CR83) 2021; 384
Mai, Guo, Zhao, Ma, Hou, Yang (CR98) 2020; 354
Ndeupen, Qin, Jacobsen, Bouteau, Estanbouli, Igyártó (CR67) 2021; 24
Kumar, Qin, Jiang, Duncan, Brigham, Fishman (CR38) 2014; 3
Espeseth, Cejas, Citron, Wang, DiStefano, Callahan (CR89) 2020; 5
Del Pozo-Rodríguez, Solinís, Rodríguez-Gascón (CR81) 2016; 109
Feldmann, Czub, Jones, Dick, Garbutt, Grolla (CR86) 2002; 191
Yang, Gong, Wang, Zhao, Zhao, Zhang (CR77) 2022; 14
Maruggi, Zhang, Li, Ulmer, Yu (CR3) 2019; 27
Jangra, Landers, Laghlali, Rathnasinghe, Warang, Park (CR80) 2023; 8
Hekele, Bertholet, Archer, Gibson, Palladino, Brito (CR7) 2013; 2
Judge, McClintock, Phelps, Maclachlan (CR46) 2006; 13
Mui, Tam, Jayaraman, Ansell, Du, Tam (CR44) 2013; 2
Zhang, Sun, Wang, Jankovic, Dong (CR28) 2021; 121
Verbeke, Lentacker, Smedt, Dewitte (CR19) 2019; 28
Meng, Chen, Li, Welte, Shen (CR21) 2021; 384
Rodrigueza, Pritchard, Hope (CR58) 1993; 1153
VanBlargan, Himansu, Foreman, Ebel, Pierson, Diamond (CR92) 2018; 25
Hajj (CR20) 2017; 2
Kulkarni, Cullis, van der Meel (CR25) 2018; 28
Vhora, Lalani, Bhatt, Patil, Misra (CR37) 2019; 563
Akinc, Querbes, De, Qin, Frank-Kamenetsky, Jayaprakash (CR51) 2010; 18
Hou, Zaks, Langer, Dong (CR26) 2021; 6
Lee, Kim, Seo, Kim, Chang, Lee (CR101) 2020; 8
Phua, Leong, Nair (CR11) 2013; 166
Schoenmaker, Witzigmann, Kulkarni, Verbeke, Kersten, Jiskoot (CR24) 2021; 601
Lonez, Vandenbranden, Ruysschaert (CR70) 2012; 64
Xiong, Lee, Ding, Li, Shi (CR15) 2018; 11
Sahin, Muik, Derhovanessian, Vogler, Kranz, Vormehr (CR63) 2020; 586
Sebastiani, Yanez Arteta, Lerche, Porcar, Lang, Bragg (CR45) 2021; 15
Miao, Zhang, Huang (CR106) 2021; 20
Wang, Su, Yang, Hu, Zhang, Blancafort (CR99) 2013; 21
Buschmann, Carrasco, Alishetty, Paige, Alameh, Weissman (CR35) 2021; 9
Kulkarni, Witzigmann, Leung, Tam, Cullis (CR48) 2019; 11
Semple, Chonn, Cullis (CR59) 1996; 35
Anderson, Rouphael, Widge, Jackson, Roberts, Makhene (CR84) 2020; 383
Jayaraman, Ansell, Mui, Tam, Chen, Du (CR40) 2012; 51
Hassett, Benenato, Jacquinet, Lee, Woods, Yuzhakov (CR41) 2019; 15
Xu, Yang, Li, Zhang (CR12) 2020; 21
Tanaka, Legat, Adam, Steuve, Gatot, Vandenbranden (CR71) 2008; 38
Zhao, Glass, Chen, Yang, Kaplan, Xu (CR33) 2021; 10
Handy, Antonarakis (CR103) 2018; 14
Kim, Eygeris, Gupta, Sahay (CR17) 2021; 170
Paunovska, Gil, Lokugamage, Sago, Sato, Lando (CR56) 2018; 12
KJ Kauffman (2102_CR61) 2015; 15
A Del Pozo-Rodríguez (2102_CR81) 2016; 109
Y Eygeris (2102_CR31) 2022; 55
Q Song (2102_CR104) 2018; 196
E Samaridou (2102_CR29) 2020; 154–155
D Laczkó (2102_CR68) 2020; 53
CE Dunbar (2102_CR5) 2018
CA Dinarello (2102_CR65) 2018; 281
A Akinc (2102_CR51) 2010; 18
WV Rodrigueza (2102_CR58) 1993; 1153
FP Polack (2102_CR85) 2020; 383
X Zhao (2102_CR32) 2020; 59
KK Phua (2102_CR11) 2013; 166
Y Zhang (2102_CR28) 2021; 121
F Ponti (2102_CR27) 2021; 235
Y Wang (2102_CR99) 2013; 21
S Patel (2102_CR57) 2020; 11
E Hacisuleyman (2102_CR22) 2021; 384
P Patel (2102_CR36) 2021; 42
X Hou (2102_CR26) 2021; 6
K Lee (2102_CR101) 2020; 8
R Zhang (2102_CR100) 2018; 292
J Kim (2102_CR17) 2021; 170
T Tanaka (2102_CR66) 2014; 6
A Lamoot (2102_CR79) 2024; 20
LA VanBlargan (2102_CR92) 2018; 25
MD Buschmann (2102_CR35) 2021; 9
Y Mai (2102_CR98) 2020; 354
I Koltover (2102_CR60) 1998; 281
T Tanaka (2102_CR71) 2008; 38
J Ramos da Silva (2102_CR102) 2023; 15
S Xu (2102_CR12) 2020; 21
YY Tam (2102_CR39) 2013; 5
C Grunwitz (2102_CR95) 2017; 405
LM Snell (2102_CR108) 2017; 38
AS Espeseth (2102_CR89) 2020; 5
J Yang (2102_CR96) 2019; 11
L Schoenmaker (2102_CR24) 2021; 601
K Paunovska (2102_CR56) 2018; 12
X Zhao (2102_CR33) 2021; 10
S Chen (2102_CR54) 2016; 235
U Sahin (2102_CR63) 2020; 586
EJ Anderson (2102_CR84) 2020; 383
DJA Crommelin (2102_CR23) 2021; 110
M Yarchoan (2102_CR109) 2017; 17
PJ Lin (2102_CR75) 2013; 9
S Saxena (2102_CR91) 2009; 136
S Jangra (2102_CR80) 2023; 8
RC Ryals (2102_CR53) 2020; 15
H Feldmann (2102_CR86) 2002; 191
BL Mui (2102_CR44) 2013; 2
SC Semple (2102_CR59) 1996; 35
F Rizvi (2102_CR94) 2021; 12
EE Walsh (2102_CR64) 2020; 383
L Yang (2102_CR77) 2022; 14
A Rusnock (2102_CR82) 2009; 83
SD Li (2102_CR50) 2008; 5
R Verbeke (2102_CR19) 2019; 28
S Lei (2102_CR97) 2020; 17
A Judge (2102_CR46) 2006; 13
JA Kulkarni (2102_CR25) 2018; 28
M Jayaraman (2102_CR40) 2012; 51
KAWK Hajj (2102_CR20) 2017; 2
MP Lokugamage (2102_CR47) 2021; 5
S Ndeupen (2102_CR67) 2021; 24
A Hekele (2102_CR7) 2013; 2
Q Xiong (2102_CR15) 2018; 11
H Zhang (2102_CR105) 2021
I Vhora (2102_CR37) 2019; 563
SP Teo (2102_CR2) 2022; 35
C Iavarone (2102_CR4) 2017; 16
M Jinek (2102_CR6) 2012; 337
L Miao (2102_CR106) 2021; 20
G Maruggi (2102_CR3) 2019; 27
CE Handy (2102_CR103) 2018; 14
C Zhang (2102_CR18) 2019
BN Aldosari (2102_CR13) 2021; 13
MG Alameh (2102_CR74) 2021; 54
MA Oberli (2102_CR55) 2017; 17
NAC Jackson (2102_CR8) 2020; 5
KJ Hassett (2102_CR41) 2019; 15
T Suzuki (2102_CR42) 2020; 588
V Kumar (2102_CR38) 2014; 3
C Lonez (2102_CR70) 2012; 64
MS Gebre (2102_CR16) 2021; 184
T Ura (2102_CR87) 2021; 39
W Zhao (2102_CR14) 2019; 217
F Sebastiani (2102_CR45) 2021; 15
W Yang (2102_CR88) 2012; 7
M Pine (2102_CR90) 2023; 31
LA Jackson (2102_CR62) 2020; 383
M Cobb (2102_CR9) 2015; 25
PS Kowalski (2102_CR73) 2019; 27
U Sahin (2102_CR110) 2017; 547
SW Tse (2102_CR78) 2021; 29
JA Kulkarni (2102_CR48) 2019; 11
LR Baden (2102_CR83) 2021; 384
JL Tanyi (2102_CR107) 2018
K Lederer (2102_CR69) 2020; 53
CP Karch (2102_CR1) 2016; 120
AK Blakney (2102_CR72) 2019; 26
JG Rurik (2102_CR93) 2022; 375
JW Holland (2102_CR43) 1996; 35
H Tanaka (2102_CR30) 2020; 30
J Heyes (2102_CR34) 2005; 107
S Cui (2102_CR76) 2018; 7
L Miao (2102_CR52) 2020; 11
C Meng (2102_CR21) 2021; 384
H Zhang (2102_CR49) 2020; 12
JA Wolff (2102_CR10) 1990; 247
References_xml – volume: 12
  start-page: 1042
  issue: 11
  year: 2020
  ident: CR49
  article-title: Aerosolizable lipid nanoparticles for pulmonary delivery of mrna through design of experiments
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12111042
– volume: 35
  start-page: 2618
  issue: 8
  year: 1996
  end-page: 2624
  ident: CR43
  article-title: Poly(ethylene glycol)–lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine
  publication-title: Biochemistry
  doi: 10.1021/bi952000v
– volume: 166
  start-page: 227
  issue: 3
  year: 2013
  end-page: 233
  ident: CR11
  article-title: Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2012.12.029
– volume: 10
  issue: 4
  year: 2021
  ident: CR33
  article-title: mRNA delivery using BIOREDUCIBLE LIPIDOID nanoparticles facilitates neural differentiation of human mesenchymal stem cells
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.202000938
– volume: 375
  start-page: 91
  issue: 6576
  year: 2022
  end-page: 96
  ident: CR93
  article-title: CAR T cells produced in vivo to treat cardiac injury
  publication-title: Science
  doi: 10.1126/science.abm0594
– volume: 17
  start-page: 1326
  issue: 3
  year: 2017
  end-page: 1335
  ident: CR55
  article-title: Lipid nanoparticle assisted mrna delivery for potent cancer immunotherapy
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.6b03329
– volume: 1153
  start-page: 9
  issue: 1
  year: 1993
  end-page: 19
  ident: CR58
  article-title: The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0005-2736(93)90270-A
– volume: 35
  start-page: 2521
  issue: 8
  year: 1996
  end-page: 2525
  ident: CR59
  article-title: Influence of cholesterol on the association of plasma proteins with liposomes
  publication-title: Biochemistry
  doi: 10.1021/bi950414i
– volume: 196
  start-page: 11
  year: 2018
  end-page: 21
  ident: CR104
  article-title: Therapeutic cancer vaccines: From initial findings to prospects
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2018.01.011
– volume: 8
  start-page: 96
  issue: 1
  year: 2023
  ident: CR80
  article-title: Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-023-00691-1
– volume: 5
  start-page: 498
  issue: 3
  year: 2013
  end-page: 507
  ident: CR39
  article-title: Advances in lipid nanoparticles for siRNA delivery
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics5030498
– volume: 5
  start-page: 16
  issue: 1
  year: 2020
  ident: CR89
  article-title: Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-0163-z
– volume: 292
  start-page: 256
  year: 2018
  end-page: 276
  ident: CR100
  article-title: Biomaterials for vaccine-based cancer immunotherapy
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2018.10.008
– volume: 38
  start-page: 1351
  issue: 5
  year: 2008
  end-page: 1357
  ident: CR71
  article-title: DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through toll-like receptor 4
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200737998
– volume: 20
  start-page: 41
  issue: 1
  year: 2021
  ident: CR106
  article-title: mRNA vaccine for cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 26
  start-page: 363
  issue: 9
  year: 2019
  end-page: 372
  ident: CR72
  article-title: Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA
  publication-title: Gene Ther
  doi: 10.1038/s41434-019-0095-2
– volume: 54
  start-page: 2877
  issue: 12
  year: 2021
  end-page: 92.e7
  ident: CR74
  article-title: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.11.001
– volume: 9
  start-page: 233
  issue: 2
  year: 2013
  end-page: 246
  ident: CR75
  article-title: Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2012.05.019
– volume: 17
  start-page: 3378
  issue: 9
  year: 2020
  end-page: 3391
  ident: CR97
  article-title: Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.0c00451
– volume: 384
  start-page: 2212
  issue: 23
  year: 2021
  end-page: 2218
  ident: CR22
  article-title: Vaccine breakthrough infections with SARS-CoV-2 variants
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2105000
– volume: 14
  start-page: 2682
  issue: 12
  year: 2022
  ident: CR77
  article-title: Recent advances in lipid nanoparticles for delivery of mRNA
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics14122682
– volume: 15
  start-page: 1
  year: 2019
  end-page: 11
  ident: CR41
  article-title: Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2019.01.013
– volume: 281
  start-page: 78
  issue: 5373
  year: 1998
  end-page: 81
  ident: CR60
  article-title: An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery
  publication-title: Science
  doi: 10.1126/science.281.5373.78
– volume: 12
  start-page: 8341
  issue: 8
  year: 2018
  end-page: 8349
  ident: CR56
  article-title: Analyzing 2000 in vivo drug delivery data points reveals cholesterol structure impacts nanoparticle delivery
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b03640
– volume: 281
  start-page: 8
  issue: 1
  year: 2018
  end-page: 27
  ident: CR65
  article-title: Overview of the IL-1 family in innate inflammation and acquired immunity
  publication-title: Immunol Rev
  doi: 10.1111/imr.12621
– volume: 170
  start-page: 83
  year: 2021
  end-page: 112
  ident: CR17
  article-title: Self-assembled mRNA vaccines
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.12.014
– volume: 383
  start-page: 1920
  issue: 20
  year: 2020
  end-page: 1931
  ident: CR62
  article-title: An mRNA vaccine against sars-cov-2 - preliminary report
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2022483
– volume: 109
  start-page: 184
  year: 2016
  end-page: 193
  ident: CR81
  article-title: Applications of lipid nanoparticles in gene therapy
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2016.10.016
– volume: 18
  start-page: 1357
  issue: 7
  year: 2010
  end-page: 1364
  ident: CR51
  article-title: Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
  publication-title: Mol Ther
  doi: 10.1038/mt.2010.85
– volume: 547
  start-page: 222
  issue: 7662
  year: 2017
  end-page: 226
  ident: CR110
  article-title: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
  publication-title: Nature
  doi: 10.1038/nature23003
– volume: 59
  start-page: 20083
  issue: 45
  year: 2020
  end-page: 20089
  ident: CR32
  article-title: Imidazole-based synthetic LIPIDOIDS for in vivo MRNA delivery into primary t lymphocytes
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.202008082
– volume: 6
  start-page: 1078
  issue: 12
  year: 2021
  end-page: 1094
  ident: CR26
  article-title: Lipid nanoparticles for mRNA delivery
  publication-title: Nat Rev Mater
  doi: 10.1038/s41578-021-00358-0
– volume: 7
  start-page: 473
  issue: 3
  year: 2018
  end-page: 479
  ident: CR76
  article-title: Correlation of the cytotoxic effects of cationic lipids with their headgroups
  publication-title: Toxicol Res (Camb)
  doi: 10.1039/C8TX00005K
– volume: 405
  start-page: 145
  year: 2017
  end-page: 164
  ident: CR95
  article-title: mRNA cancer vaccines-messages that prevail
  publication-title: Curr Top Microbiol Immunol
– volume: 588
  year: 2020
  ident: CR42
  article-title: PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2020.119792
– volume: 11
  start-page: 21733
  issue: 45
  year: 2019
  end-page: 21739
  ident: CR48
  article-title: On the role of helper lipids in lipid nanoparticle formulations of siRNA
  publication-title: Nanoscale
  doi: 10.1039/C9NR09347H
– volume: 39
  start-page: 197
  issue: 2
  year: 2021
  end-page: 201
  ident: CR87
  article-title: New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.11.054
– volume: 29
  start-page: 2227
  issue: 7
  year: 2021
  end-page: 2238
  ident: CR78
  article-title: mRNA-encoded, constitutively active STING(V155M) is a potent genetic adjuvant of antigen-specific CD8(+) T cell response
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.03.002
– volume: 7
  issue: 10
  year: 2012
  ident: CR88
  article-title: Relationship between humidity and influenza A viability in droplets and implications for influenza’s seasonality
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0046789
– volume: 64
  start-page: 1749
  issue: 15
  year: 2012
  end-page: 1758
  ident: CR70
  article-title: Cationic lipids activate intracellular signaling pathways
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2012.05.009
– volume: 28
  start-page: 146
  issue: 3
  year: 2018
  end-page: 157
  ident: CR25
  article-title: Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2018.0721
– volume: 14
  start-page: 907
  issue: 10
  year: 2018
  end-page: 917
  ident: CR103
  article-title: Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
  publication-title: Future Oncol
  doi: 10.2217/fon-2017-0531
– volume: 21
  start-page: 6582
  issue: 18
  year: 2020
  ident: CR12
  article-title: mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21186582
– volume: 9
  start-page: 65
  issue: 1
  year: 2021
  ident: CR35
  article-title: Nanomaterial delivery systems for mRNA Vaccines
  publication-title: Vaccines (Basel).
  doi: 10.3390/vaccines9010065
– volume: 235
  year: 2021
  ident: CR27
  article-title: Cationic lipids for gene delivery: many players, one goal
  publication-title: Chem Phys Lipids
  doi: 10.1016/j.chemphyslip.2020.105032
– volume: 55
  start-page: 2
  issue: 1
  year: 2022
  end-page: 12
  ident: CR31
  article-title: Chemistry of lipid nanoparticles for RNA delivery
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.1c00544
– volume: 136
  start-page: 36
  issue: 1–2
  year: 2009
  end-page: 44
  ident: CR91
  article-title: Induction of immune responses and protection in mice against rabies using a self-replicating RNA vaccine encoding rabies virus glycoprotein
  publication-title: Vet Microbiol
  doi: 10.1016/j.vetmic.2008.10.030
– volume: 31
  start-page: 2702
  issue: 9
  year: 2023
  end-page: 2714
  ident: CR90
  article-title: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2023.07.022
– volume: 25
  start-page: R526
  issue: 13
  year: 2015
  end-page: R532
  ident: CR9
  article-title: Who discovered messenger RNA?
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2015.05.032
– volume: 247
  start-page: 1465
  issue: 4949 Pt 1
  year: 1990
  end-page: 1468
  ident: CR10
  article-title: Direct gene transfer into mouse muscle in vivo
  publication-title: Science
  doi: 10.1126/science.1690918
– volume: 217
  year: 2019
  ident: CR14
  article-title: RNA delivery biomaterials for the treatment of genetic and rare diseases
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2019.119291
– volume: 601
  year: 2021
  ident: CR24
  article-title: mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2021.120586
– volume: 15
  start-page: 3464
  issue: 686
  year: 2023
  ident: CR102
  article-title: Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.abn3464
– volume: 83
  start-page: 17
  issue: 1
  year: 2009
  end-page: 36
  ident: CR82
  article-title: Catching cowpox: the early spread of smallpox vaccination, 1798–1810
  publication-title: Bull Hist Med
  doi: 10.1353/bhm.0.0160
– volume: 28
  start-page: 100766
  year: 2019
  ident: CR19
  article-title: Three decades of messenger RNA vaccine development
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2019.100766
– volume: 5
  start-page: 1059
  issue: 9
  year: 2021
  end-page: 1068
  ident: CR47
  article-title: Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
  publication-title: Nat Biomed Eng
  doi: 10.1038/s41551-021-00786-x
– volume: 27
  start-page: 757
  issue: 4
  year: 2019
  end-page: 772
  ident: CR3
  article-title: mRNA as a transformative technology for vaccine development to control infectious diseases
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.01.020
– volume: 586
  start-page: 594
  issue: 7830
  year: 2020
  end-page: 599
  ident: CR63
  article-title: COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses
  publication-title: Nature
  doi: 10.1038/s41586-020-2814-7
– volume: 11
  start-page: 5281
  issue: 10
  year: 2018
  end-page: 5309
  ident: CR15
  article-title: Biomedical applications of mRNA nanomedicine
  publication-title: Nano Res
  doi: 10.1007/s12274-018-2146-1
– volume: 107
  start-page: 276
  issue: 2
  year: 2005
  end-page: 287
  ident: CR34
  article-title: Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2005.06.014
– volume: 51
  start-page: 8529
  issue: 34
  year: 2012
  end-page: 8533
  ident: CR40
  article-title: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201203263
– volume: 2
  issue: 12
  year: 2013
  ident: CR44
  article-title: Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of sirna lipid nanoparticles
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2013.66
– volume: 154–155
  start-page: 37
  year: 2020
  end-page: 63
  ident: CR29
  article-title: Lipid nanoparticles for nucleic acid delivery: current perspectives
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.06.002
– volume: 2
  issue: 8
  year: 2013
  ident: CR7
  article-title: Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice
  publication-title: Emerg Microbes Infect
– year: 2018
  ident: CR107
  article-title: Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aao5931
– volume: 383
  start-page: 2439
  issue: 25
  year: 2020
  end-page: 2450
  ident: CR64
  article-title: Safety and immunogenicity of two rna-based covid-19 vaccine candidates
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027906
– volume: 20
  issue: 10
  year: 2024
  ident: CR79
  article-title: Lipid nanoparticle encapsulation empowers poly(I:C) to activate cytoplasmic RLRs and thereby increases its adjuvanticity
  publication-title: Small
  doi: 10.1002/smll.202306892
– volume: 110
  start-page: 997
  issue: 3
  year: 2021
  end-page: 1001
  ident: CR23
  article-title: Addressing the cold reality of mRNA vaccine stability
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2020.12.006
– volume: 17
  start-page: 209
  issue: 4
  year: 2017
  end-page: 222
  ident: CR109
  article-title: Targeting neoantigens to augment antitumour immunity
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.154
– volume: 2
  start-page: 17056
  year: 2017
  ident: CR20
  article-title: Tools for translation: non-viral materials for therapeutic mRNA delivery
  publication-title: Nat Rev Mater
  doi: 10.1038/natrevmats.2017.56
– volume: 120
  start-page: 1
  year: 2016
  end-page: 14
  ident: CR1
  article-title: Vaccine technologies: From whole organisms to rationally designed protein assemblies
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2016.05.001
– volume: 121
  start-page: 12181
  issue: 20
  year: 2021
  end-page: 12277
  ident: CR28
  article-title: Lipids and lipid derivatives for RNA delivery
  publication-title: Chem Rev
  doi: 10.1021/acs.chemrev.1c00244
– year: 2021
  ident: CR105
  article-title: Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.2005191118
– volume: 15
  start-page: 6709
  issue: 4
  year: 2021
  end-page: 6722
  ident: CR45
  article-title: Apolipoprotein E binding drives structural and compositional rearrangement of mrna-containing lipid nanoparticles
  publication-title: ACS Nano
  doi: 10.1021/acsnano.0c10064
– year: 2019
  ident: CR18
  article-title: Advances in mRNA vaccines for infectious diseases
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00594
– volume: 5
  start-page: 496
  issue: 4
  year: 2008
  end-page: 504
  ident: CR50
  article-title: Pharmacokinetics and biodistribution of nanoparticles
  publication-title: Mol Pharm
  doi: 10.1021/mp800049w
– volume: 12
  start-page: 613
  issue: 1
  year: 2021
  ident: CR94
  article-title: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-20903-3
– volume: 235
  start-page: 236
  year: 2016
  end-page: 244
  ident: CR54
  article-title: Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2016.05.059
– volume: 24
  start-page: 103479
  issue: 12
  year: 2021
  ident: CR67
  article-title: The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
  publication-title: iScience
  doi: 10.1016/j.isci.2021.103479
– volume: 53
  start-page: 1281-95.e5
  issue: 6
  year: 2020
  ident: CR69
  article-title: SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.11.009
– volume: 337
  start-page: 816
  issue: 6096
  year: 2012
  end-page: 821
  ident: CR6
  article-title: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
  publication-title: Science
  doi: 10.1126/science.1225829
– volume: 16
  start-page: 871
  issue: 9
  year: 2017
  end-page: 881
  ident: CR4
  article-title: Mechanism of action of mRNA-based vaccines
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2017.1355245
– volume: 42
  start-page: 448
  issue: 6
  year: 2021
  end-page: 460
  ident: CR36
  article-title: The importance of apparent pka in the development of nanoparticles encapsulating siRNA and mRNA
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2021.03.002
– volume: 5
  start-page: 11
  year: 2020
  ident: CR8
  article-title: The promise of mRNA vaccines: a biotech and industrial perspective
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-0159-8
– volume: 354
  year: 2020
  ident: CR98
  article-title: Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity
  publication-title: Cell Immunol
  doi: 10.1016/j.cellimm.2020.104143
– volume: 38
  start-page: 542
  issue: 8
  year: 2017
  end-page: 557
  ident: CR108
  article-title: Type I interferon in chronic virus infection and cancer
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2017.05.005
– volume: 15
  issue: 10
  year: 2020
  ident: CR53
  article-title: The effects of PEGylation on LNP based mRNA delivery to the eye
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0241006
– volume: 53
  start-page: 724
  issue: 4
  year: 2020
  end-page: 32.e7
  ident: CR68
  article-title: A single immunization with nucleoside-modified mrna vaccines elicits strong cellular and humoral immune responses against sars-cov-2 in mice
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.07.019
– volume: 3
  issue: 11
  year: 2014
  ident: CR38
  article-title: Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2014.61
– volume: 384
  start-page: 2212
  year: 2021
  end-page: 22218
  ident: CR21
  article-title: Nanoplatforms for mRNA therapeutics
  publication-title: Advanced Therapeutics.
– volume: 35
  start-page: 947
  issue: 6
  year: 2022
  end-page: 951
  ident: CR2
  article-title: Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
  publication-title: J Pharm Pract
  doi: 10.1177/08971900211009650
– volume: 8
  start-page: 1101
  issue: 4
  year: 2020
  end-page: 1105
  ident: CR101
  article-title: Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy
  publication-title: Biomater Sci
  doi: 10.1039/C9BM01564G
– volume: 563
  start-page: 324
  year: 2019
  end-page: 336
  ident: CR37
  article-title: Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2019.04.006
– volume: 383
  start-page: 2427
  issue: 25
  year: 2020
  end-page: 2438
  ident: CR84
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2028436
– volume: 13
  start-page: 328
  issue: 2
  year: 2006
  end-page: 337
  ident: CR46
  article-title: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2005.09.014
– volume: 15
  start-page: 7300
  issue: 11
  year: 2015
  end-page: 7306
  ident: CR61
  article-title: Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.5b02497
– volume: 25
  start-page: 3382
  issue: 12
  year: 2018
  end-page: 92.e3
  ident: CR92
  article-title: An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.11.082
– volume: 384
  start-page: 403
  issue: 5
  year: 2021
  end-page: 416
  ident: CR83
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
– volume: 11
  start-page: 21782
  issue: 45
  year: 2019
  end-page: 21789
  ident: CR96
  article-title: Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant
  publication-title: Nanoscale
  doi: 10.1039/C9NR05475H
– volume: 21
  start-page: 358
  issue: 2
  year: 2013
  end-page: 367
  ident: CR99
  article-title: Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy
  publication-title: Mol Ther
  doi: 10.1038/mt.2012.250
– volume: 184
  start-page: 1589
  issue: 6
  year: 2021
  end-page: 1603
  ident: CR16
  article-title: Novel approaches for vaccine development
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.030
– volume: 11
  start-page: 2424
  issue: 1
  year: 2020
  ident: CR52
  article-title: Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-16248-y
– volume: 27
  start-page: 710
  issue: 4
  year: 2019
  end-page: 728
  ident: CR73
  article-title: Delivering the messenger: advances in technologies for therapeutic mrna delivery
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.02.012
– volume: 30
  start-page: 1910575
  issue: 34
  year: 2020
  ident: CR30
  article-title: Self-Degradable lipid-like materials based on "hydrolysis accelerated by the intra-particle enrichment of reactant (hyper)" for messenger RNA delivery
  publication-title: Adv Funct Mater
  doi: 10.1002/adfm.201910575
– volume: 11
  start-page: 983
  issue: 1
  year: 2020
  ident: CR57
  article-title: Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14527-2
– volume: 13
  start-page: 206
  issue: 2
  year: 2021
  ident: CR13
  article-title: Lipid nanoparticles as delivery systems for RNA-based vaccines
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13020206
– volume: 383
  start-page: 2603
  issue: 27
  year: 2020
  end-page: 2615
  ident: CR85
  article-title: Safety and efficacy of the BNT162B2 mRNA covid-19 vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
– year: 2018
  ident: CR5
  article-title: Gene therapy comes of age
  publication-title: Science
  doi: 10.1126/science.aan4672
– volume: 6
  issue: 10
  year: 2014
  ident: CR66
  article-title: IL-6 in inflammation, immunity, and disease
  publication-title: Cold Spring Harb Perspect Biol
  doi: 10.1101/cshperspect.a016295
– volume: 191
  start-page: 63
  issue: 2
  year: 2002
  end-page: 74
  ident: CR86
  article-title: Emerging and re-emerging infectious diseases
  publication-title: Med Microbiol Immunol
  doi: 10.1007/s00430-002-0122-5
– volume: 24
  start-page: 103479
  issue: 12
  year: 2021
  ident: 2102_CR67
  publication-title: iScience
  doi: 10.1016/j.isci.2021.103479
– volume: 20
  start-page: 41
  issue: 1
  year: 2021
  ident: 2102_CR106
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 281
  start-page: 78
  issue: 5373
  year: 1998
  ident: 2102_CR60
  publication-title: Science
  doi: 10.1126/science.281.5373.78
– volume: 13
  start-page: 206
  issue: 2
  year: 2021
  ident: 2102_CR13
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13020206
– year: 2019
  ident: 2102_CR18
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00594
– volume: 55
  start-page: 2
  issue: 1
  year: 2022
  ident: 2102_CR31
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.1c00544
– volume: 54
  start-page: 2877
  issue: 12
  year: 2021
  ident: 2102_CR74
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.11.001
– volume: 354
  year: 2020
  ident: 2102_CR98
  publication-title: Cell Immunol
  doi: 10.1016/j.cellimm.2020.104143
– volume: 15
  start-page: 3464
  issue: 686
  year: 2023
  ident: 2102_CR102
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.abn3464
– volume: 1153
  start-page: 9
  issue: 1
  year: 1993
  ident: 2102_CR58
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0005-2736(93)90270-A
– volume: 21
  start-page: 358
  issue: 2
  year: 2013
  ident: 2102_CR99
  publication-title: Mol Ther
  doi: 10.1038/mt.2012.250
– volume: 35
  start-page: 947
  issue: 6
  year: 2022
  ident: 2102_CR2
  publication-title: J Pharm Pract
  doi: 10.1177/08971900211009650
– volume: 20
  issue: 10
  year: 2024
  ident: 2102_CR79
  publication-title: Small
  doi: 10.1002/smll.202306892
– volume: 12
  start-page: 613
  issue: 1
  year: 2021
  ident: 2102_CR94
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-20903-3
– volume: 31
  start-page: 2702
  issue: 9
  year: 2023
  ident: 2102_CR90
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2023.07.022
– volume: 15
  start-page: 6709
  issue: 4
  year: 2021
  ident: 2102_CR45
  publication-title: ACS Nano
  doi: 10.1021/acsnano.0c10064
– volume: 11
  start-page: 5281
  issue: 10
  year: 2018
  ident: 2102_CR15
  publication-title: Nano Res
  doi: 10.1007/s12274-018-2146-1
– volume: 337
  start-page: 816
  issue: 6096
  year: 2012
  ident: 2102_CR6
  publication-title: Science
  doi: 10.1126/science.1225829
– volume: 53
  start-page: 1281-95.e5
  issue: 6
  year: 2020
  ident: 2102_CR69
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.11.009
– volume: 2
  issue: 12
  year: 2013
  ident: 2102_CR44
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2013.66
– volume: 12
  start-page: 8341
  issue: 8
  year: 2018
  ident: 2102_CR56
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b03640
– volume: 586
  start-page: 594
  issue: 7830
  year: 2020
  ident: 2102_CR63
  publication-title: Nature
  doi: 10.1038/s41586-020-2814-7
– volume: 15
  start-page: 7300
  issue: 11
  year: 2015
  ident: 2102_CR61
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.5b02497
– volume: 9
  start-page: 233
  issue: 2
  year: 2013
  ident: 2102_CR75
  publication-title: Nanomedicine
  doi: 10.1016/j.nano.2012.05.019
– volume: 184
  start-page: 1589
  issue: 6
  year: 2021
  ident: 2102_CR16
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.030
– volume: 292
  start-page: 256
  year: 2018
  ident: 2102_CR100
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2018.10.008
– volume: 53
  start-page: 724
  issue: 4
  year: 2020
  ident: 2102_CR68
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.07.019
– volume: 28
  start-page: 100766
  year: 2019
  ident: 2102_CR19
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2019.100766
– volume: 42
  start-page: 448
  issue: 6
  year: 2021
  ident: 2102_CR36
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2021.03.002
– volume: 15
  start-page: 1
  year: 2019
  ident: 2102_CR41
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2019.01.013
– volume: 11
  start-page: 2424
  issue: 1
  year: 2020
  ident: 2102_CR52
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-16248-y
– volume: 7
  start-page: 473
  issue: 3
  year: 2018
  ident: 2102_CR76
  publication-title: Toxicol Res (Camb)
  doi: 10.1039/C8TX00005K
– volume: 5
  start-page: 16
  issue: 1
  year: 2020
  ident: 2102_CR89
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-0163-z
– volume: 384
  start-page: 403
  issue: 5
  year: 2021
  ident: 2102_CR83
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
– volume: 11
  start-page: 21733
  issue: 45
  year: 2019
  ident: 2102_CR48
  publication-title: Nanoscale
  doi: 10.1039/C9NR09347H
– volume: 235
  year: 2021
  ident: 2102_CR27
  publication-title: Chem Phys Lipids
  doi: 10.1016/j.chemphyslip.2020.105032
– volume: 11
  start-page: 983
  issue: 1
  year: 2020
  ident: 2102_CR57
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14527-2
– volume: 6
  start-page: 1078
  issue: 12
  year: 2021
  ident: 2102_CR26
  publication-title: Nat Rev Mater
  doi: 10.1038/s41578-021-00358-0
– volume: 14
  start-page: 907
  issue: 10
  year: 2018
  ident: 2102_CR103
  publication-title: Future Oncol
  doi: 10.2217/fon-2017-0531
– volume: 109
  start-page: 184
  year: 2016
  ident: 2102_CR81
  publication-title: Eur J Pharm Biopharm
  doi: 10.1016/j.ejpb.2016.10.016
– volume: 107
  start-page: 276
  issue: 2
  year: 2005
  ident: 2102_CR34
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2005.06.014
– volume: 166
  start-page: 227
  issue: 3
  year: 2013
  ident: 2102_CR11
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2012.12.029
– volume: 7
  issue: 10
  year: 2012
  ident: 2102_CR88
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0046789
– volume: 563
  start-page: 324
  year: 2019
  ident: 2102_CR37
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2019.04.006
– volume: 18
  start-page: 1357
  issue: 7
  year: 2010
  ident: 2102_CR51
  publication-title: Mol Ther
  doi: 10.1038/mt.2010.85
– volume: 247
  start-page: 1465
  issue: 4949 Pt 1
  year: 1990
  ident: 2102_CR10
  publication-title: Science
  doi: 10.1126/science.1690918
– volume: 25
  start-page: R526
  issue: 13
  year: 2015
  ident: 2102_CR9
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2015.05.032
– volume: 17
  start-page: 3378
  issue: 9
  year: 2020
  ident: 2102_CR97
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.0c00451
– volume: 383
  start-page: 1920
  issue: 20
  year: 2020
  ident: 2102_CR62
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2022483
– volume: 136
  start-page: 36
  issue: 1–2
  year: 2009
  ident: 2102_CR91
  publication-title: Vet Microbiol
  doi: 10.1016/j.vetmic.2008.10.030
– volume: 2
  start-page: 17056
  year: 2017
  ident: 2102_CR20
  publication-title: Nat Rev Mater
  doi: 10.1038/natrevmats.2017.56
– volume: 16
  start-page: 871
  issue: 9
  year: 2017
  ident: 2102_CR4
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2017.1355245
– volume: 154–155
  start-page: 37
  year: 2020
  ident: 2102_CR29
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.06.002
– volume: 38
  start-page: 542
  issue: 8
  year: 2017
  ident: 2102_CR108
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2017.05.005
– volume: 17
  start-page: 209
  issue: 4
  year: 2017
  ident: 2102_CR109
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.154
– volume: 35
  start-page: 2521
  issue: 8
  year: 1996
  ident: 2102_CR59
  publication-title: Biochemistry
  doi: 10.1021/bi950414i
– volume: 384
  start-page: 2212
  year: 2021
  ident: 2102_CR21
  publication-title: Advanced Therapeutics.
– volume: 8
  start-page: 96
  issue: 1
  year: 2023
  ident: 2102_CR80
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-023-00691-1
– volume: 17
  start-page: 1326
  issue: 3
  year: 2017
  ident: 2102_CR55
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.6b03329
– volume: 29
  start-page: 2227
  issue: 7
  year: 2021
  ident: 2102_CR78
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.03.002
– volume: 2
  issue: 8
  year: 2013
  ident: 2102_CR7
  publication-title: Emerg Microbes Infect
– volume: 83
  start-page: 17
  issue: 1
  year: 2009
  ident: 2102_CR82
  publication-title: Bull Hist Med
  doi: 10.1353/bhm.0.0160
– volume: 21
  start-page: 6582
  issue: 18
  year: 2020
  ident: 2102_CR12
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21186582
– volume: 35
  start-page: 2618
  issue: 8
  year: 1996
  ident: 2102_CR43
  publication-title: Biochemistry
  doi: 10.1021/bi952000v
– volume: 5
  start-page: 11
  year: 2020
  ident: 2102_CR8
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-0159-8
– volume: 383
  start-page: 2427
  issue: 25
  year: 2020
  ident: 2102_CR84
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2028436
– volume: 26
  start-page: 363
  issue: 9
  year: 2019
  ident: 2102_CR72
  publication-title: Gene Ther
  doi: 10.1038/s41434-019-0095-2
– volume: 39
  start-page: 197
  issue: 2
  year: 2021
  ident: 2102_CR87
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2020.11.054
– volume: 588
  year: 2020
  ident: 2102_CR42
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2020.119792
– volume: 3
  issue: 11
  year: 2014
  ident: 2102_CR38
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2014.61
– volume: 59
  start-page: 20083
  issue: 45
  year: 2020
  ident: 2102_CR32
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.202008082
– volume: 10
  issue: 4
  year: 2021
  ident: 2102_CR33
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.202000938
– volume: 14
  start-page: 2682
  issue: 12
  year: 2022
  ident: 2102_CR77
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics14122682
– year: 2021
  ident: 2102_CR105
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.2005191118
– volume: 383
  start-page: 2603
  issue: 27
  year: 2020
  ident: 2102_CR85
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
– volume: 25
  start-page: 3382
  issue: 12
  year: 2018
  ident: 2102_CR92
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2018.11.082
– volume: 196
  start-page: 11
  year: 2018
  ident: 2102_CR104
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2018.01.011
– volume: 121
  start-page: 12181
  issue: 20
  year: 2021
  ident: 2102_CR28
  publication-title: Chem Rev
  doi: 10.1021/acs.chemrev.1c00244
– volume: 5
  start-page: 498
  issue: 3
  year: 2013
  ident: 2102_CR39
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics5030498
– volume: 5
  start-page: 1059
  issue: 9
  year: 2021
  ident: 2102_CR47
  publication-title: Nat Biomed Eng
  doi: 10.1038/s41551-021-00786-x
– volume: 15
  issue: 10
  year: 2020
  ident: 2102_CR53
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0241006
– year: 2018
  ident: 2102_CR5
  publication-title: Science
  doi: 10.1126/science.aan4672
– volume: 384
  start-page: 2212
  issue: 23
  year: 2021
  ident: 2102_CR22
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2105000
– volume: 235
  start-page: 236
  year: 2016
  ident: 2102_CR54
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2016.05.059
– volume: 28
  start-page: 146
  issue: 3
  year: 2018
  ident: 2102_CR25
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2018.0721
– volume: 383
  start-page: 2439
  issue: 25
  year: 2020
  ident: 2102_CR64
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027906
– volume: 9
  start-page: 65
  issue: 1
  year: 2021
  ident: 2102_CR35
  publication-title: Vaccines (Basel).
  doi: 10.3390/vaccines9010065
– volume: 8
  start-page: 1101
  issue: 4
  year: 2020
  ident: 2102_CR101
  publication-title: Biomater Sci
  doi: 10.1039/C9BM01564G
– volume: 38
  start-page: 1351
  issue: 5
  year: 2008
  ident: 2102_CR71
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200737998
– volume: 217
  year: 2019
  ident: 2102_CR14
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2019.119291
– volume: 281
  start-page: 8
  issue: 1
  year: 2018
  ident: 2102_CR65
  publication-title: Immunol Rev
  doi: 10.1111/imr.12621
– volume: 30
  start-page: 1910575
  issue: 34
  year: 2020
  ident: 2102_CR30
  publication-title: Adv Funct Mater
  doi: 10.1002/adfm.201910575
– volume: 110
  start-page: 997
  issue: 3
  year: 2021
  ident: 2102_CR23
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2020.12.006
– volume: 6
  issue: 10
  year: 2014
  ident: 2102_CR66
  publication-title: Cold Spring Harb Perspect Biol
  doi: 10.1101/cshperspect.a016295
– volume: 12
  start-page: 1042
  issue: 11
  year: 2020
  ident: 2102_CR49
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12111042
– volume: 27
  start-page: 710
  issue: 4
  year: 2019
  ident: 2102_CR73
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.02.012
– volume: 547
  start-page: 222
  issue: 7662
  year: 2017
  ident: 2102_CR110
  publication-title: Nature
  doi: 10.1038/nature23003
– volume: 191
  start-page: 63
  issue: 2
  year: 2002
  ident: 2102_CR86
  publication-title: Med Microbiol Immunol
  doi: 10.1007/s00430-002-0122-5
– volume: 27
  start-page: 757
  issue: 4
  year: 2019
  ident: 2102_CR3
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.01.020
– volume: 13
  start-page: 328
  issue: 2
  year: 2006
  ident: 2102_CR46
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2005.09.014
– volume: 120
  start-page: 1
  year: 2016
  ident: 2102_CR1
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2016.05.001
– volume: 601
  year: 2021
  ident: 2102_CR24
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2021.120586
– volume: 405
  start-page: 145
  year: 2017
  ident: 2102_CR95
  publication-title: Curr Top Microbiol Immunol
– volume: 64
  start-page: 1749
  issue: 15
  year: 2012
  ident: 2102_CR70
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2012.05.009
– volume: 11
  start-page: 21782
  issue: 45
  year: 2019
  ident: 2102_CR96
  publication-title: Nanoscale
  doi: 10.1039/C9NR05475H
– volume: 5
  start-page: 496
  issue: 4
  year: 2008
  ident: 2102_CR50
  publication-title: Mol Pharm
  doi: 10.1021/mp800049w
– volume: 375
  start-page: 91
  issue: 6576
  year: 2022
  ident: 2102_CR93
  publication-title: Science
  doi: 10.1126/science.abm0594
– volume: 170
  start-page: 83
  year: 2021
  ident: 2102_CR17
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.12.014
– volume: 51
  start-page: 8529
  issue: 34
  year: 2012
  ident: 2102_CR40
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201203263
– year: 2018
  ident: 2102_CR107
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aao5931
SSID ssj0008824
Score 2.4326067
SecondaryResourceType review_article
Snippet Messenger ribonucleic acid (mRNA) was discovered in 1961 as an intermediary for transferring genetic information from DNA to ribosomes for protein synthesis....
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 577
SubjectTerms 2019-nCoV Vaccine mRNA-1273
Biocompatibility
Biodegradability
Biomedical and Life Sciences
Biomedicine
Cardiovascular diseases
Cell size
Cholesterol
COVID-19 - prevention & control
COVID-19 infection
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
DNA
DNA biosynthesis
DNA vaccines
Drug delivery
Drug development
genes
Humans
Infectious diseases
Lipid bilayers
Lipids - chemistry
Liposomes
liver
Liver cancer
Liver diseases
Medical Microbiology
mRNA
mRNA Vaccines
Nanoparticles
Nanoparticles - chemistry
pH effects
Phospholipids
Plant Sciences
Polyethylene glycol
Protein biosynthesis
protein synthesis
Review Paper
Ribosomes
RNA
RNA, Messenger - genetics
SARS-CoV-2 - genetics
therapeutics
Transcription
Vaccine development
Vaccine efficacy
vaccines
Vascular diseases
Virology
viruses
SummonAdditionalLinks – databaseName: Biological Science Database (ProQuest)
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB58ghffj_oigjcNbrZtkp5kEUVByiJ72FtpmhQE7a7bVfDfO0kfq4h78ZwUJp3J5JvM5BuAc821VsLnlGc6pEGuBY14GlGEEpwpJURHua4ljyKO5XAY9esLt7Iuq2x8onPUepTZO_IrHx2pjCwf2vX4jdquUTa7WrfQWIRly5Lgu9K9fuuJET06-qgIQyQZ8qh-NFM9nWNd3qV4QlEX9VD-82D6hTZ_ZUrdAXS38V_RN2G9hp6kV9nKFiyYYhtWq2aUnzvw0KvKAUryXBCEhcQxz5JRTh7jfkkQ3JLXp7hHtHmxtRyfJC00aR5Wku-J8F0Y3N0Obu5p3WiBZkFHTik3jOVac5tEy1NEZLitdRZaXpaQCRxQLMiF5bTGkTySuW9kR2cdLk2aqtzfg6ViVJgDIH6EMa9IpeWkCYzKMJoTWihmpGIYCysPWPOTk6wmIbe9MF6SGX2yVUyCikmcYhLuwUX7zbii4Jg7-7hRQlJvxzKZacCDs3YYN5LNjqSFGb3jHEvJKG339TlzEHAyLjHE9WC_sotWJFy66Pph4MFlYygzAf6W93C-vEew1rVG6gpojmFpOnk3J7CSfUyfy8mpM_cvCOAAag
  priority: 102
  providerName: ProQuest
Title Advances in the study of LNPs for mRNA delivery and clinical applications
URI https://link.springer.com/article/10.1007/s11262-024-02102-6
https://www.ncbi.nlm.nih.gov/pubmed/39172354
https://www.proquest.com/docview/3128890160
https://www.proquest.com/docview/3095681187
https://www.proquest.com/docview/3154168917
Volume 60
WOSCitedRecordID wos001296493900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1572-994X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0008824
  issn: 0920-8569
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwED90U_DF74_6MSL4poFlbZP0cYqiIGVMkb2VpklB0E7sFPzvvaTtpvgB-tKXXMv1ksvdcXe_AzjSXGslfE55pkMa5FrQiKcRRVeCM6WE6Co3teRaxLEcjaJB3RRWNtXuTUrS3dSzZjfW4z2KNoW6OIXyeWijuZNWHYc3d9P7F31GBxoVYWAkQx7VrTLff-OzOfriY37Jjzqzc7HyP4ZXYbl2M0m_OhdrMGeKdVisBk--bcBVv0r9l-S-IOgCEocyS8Y5uY4HJUFHljwO4z7R5sHWbbyRtNCkaaIkH5Pem3B7cX57dknroQo0C7pyQrlhLNea24RZnqL3hSqss9BisIRM4IJiQS4sfjWu5JHMfSO7OutyadJU5f4WtIpxYXaA-BHGtyKVFn8mMCrDyE1ooZiRimHcqzxgjWiTrAYct3MvHpIZVLKVUIISSpyEEu7B8fSdpwpu41fq_WbHklr1ysRHiysjC5znweF0GZXGZkLSwoxfkMbCL0o7af0XGnQuGZcYznqwXZ2GKUv466Lnh4EHJ83Wzxj4md_dv5HvwVLPnh5XPLMPrcnzizmAhex1cl8-d2BejIR7SnzKM9aB9ul5PBh2bP3qoOOU4h0Q1ftg
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT9wwEB4BLYJLHzxKWmhdiZ6K1XUetnOoqlUpYsU2WqE9cLPi2JGQaJaSpdX-qP7Hjp1ktxVibxw424nszHj8TWbmG4BDw43RIuKUFyahcWkETXmeUoQSnGktRE_7riVDkWXy4iIdrcCfrhbGpVV2NtEbajMp3D_yTxEaUpk6PrQv1z-p6xrloqtdC41GLc7s7De6bPXnwTHK90MYnnwbfz2lbVcBWsQ9OaXcMlYaw13EqMwRfqAOmyJxJCQJEzigWVwKR-CMI2Uqy8jKnil6XNo812WEr12FJ4giQukzBUdzw49g1bNVpeiRyYSnbY1OU6nHQh5SvBCpd7Io__8evANu7wRm_X138vyRfakX8KwF1qTfnISXsGKrLVhvWm3OtmHQb5IdanJZEQS9xPPqkklJhtmoJgjdyY_zrE-MvXKZKjOSV4Z0ZaPk3zD_DowfYhu7sFZNKrsHJErRoxe5dIw7sdUF-qrCCM2s1Aw9fR0A62SqipZi3XX6uFILcminBwr1QHk9UDyAj_NnrhuCkaWz9zuZq9bY1Goh8ADez4fRTLjYT17ZyS3OcYST0vWWXzIH4TTjEh34AF41ajhfEm5dhFESB3DU6eViAfev9_Xy9b6DjdPx96EaDrKzN7AZuvPhU4X2YW16c2sP4Gnxa3pZ37z1J42AemB9_QtzPltO
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8lAvvCmBAkaCE7W6jhPbOSC0almx6ipaoR56i-LYliqVbNtsqfan9d917CS7oIq99cDZTmRnPo9nMjPfAHwywhgtuaCiMilNnJE0E2VG0ZQQTGspBzp0LZnIPFfHx9l0A677WhifVtnrxKCozazy_8j3OCpSlXk-tD3XpUVMD0bfzs6p7yDlI619O40WIod2cYXuW_N1fICy_hzHo-9H-z9o12GAVslAzamwjDljhI8euRJNEcSzqVJPSJIyiQOaJU56MmcccZly3KqBqQZC2bLUjuNr78F93Cr32WRqf5VdgoZrYK7K0DtTqci6ep22ao_FIqZ4OdLgcFHx9514y9C9FaQNd9_oyX_81Z7C487gJsP2hDyDDVs_h4dtC87FCxgP2ySIhpzUBI1hEvh2ycyRST5tCJr05NfPfEiMPfUZLAtS1ob05aTkz_D_Szi6i228gs16VtvXQHiGnr4slWfiSayu0IeVRmpmlWZccR0B6-VbVB31uu8AclqsSKM9JgrERBEwUYgIviyfOWuJR9bO3unlX3RKqClWwo_g43IY1YePCZW1nV3iHE9EqXzP-TVz0MxmQqFjH8F2C8nlknDrMuZpEsFuj9HVAv693jfr1_sBHiFMi8k4P3wLW7E_KiGDaAc25xeX9h08qH7PT5qL9-HQESjuGK43qjdjxA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+the+study+of+LNPs+for+mRNA+delivery+and+clinical+applications&rft.jtitle=Virus+genes&rft.au=Wang%2C+Bili&rft.au=Shen%2C+Biao&rft.au=Xiang%2C+Wenqing&rft.au=Shen%2C+Hongqiang&rft.date=2024-12-01&rft.issn=1572-994X&rft.eissn=1572-994X&rft.volume=60&rft.issue=6&rft.spage=577&rft_id=info:doi/10.1007%2Fs11262-024-02102-6&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-8569&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-8569&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-8569&client=summon